Form 4: WST Executive Chad Winters Converts RSUs, Sells Shares for Tax

West Pharmaceutical Services VP, Chief Accounting Officer Chad Winters converted restricted stock units into common stock and sold a portion for tax obligations.

Summary

• Chad Winters, VP, Chief Accounting Officer, converted 89.328 restricted stock units (RSUs) into common stock on February 20, 2026.
• Simultaneously, 30.184 shares of common stock were disposed of at a price of $241.12 per share, likely to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Winters directly owns 1,522.81 shares of common stock and 267.972 restricted stock units.
• The RSUs were granted on February 18, 2025, with 356 units vesting in four equal annual installments on February 20th each year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and continued insider ownership, with no significant discretionary selling.

Positives

• The conversion of restricted stock units indicates a vesting event, which is a positive for the executive as it represents earned compensation.
• The executive continues to hold a significant number of shares (1,522.81 common stock) and unvested RSUs (267.972), aligning his interests with shareholders.

Negatives

• A portion of the vested shares (30.184 shares) was sold, which is a common practice for tax withholding but still represents a reduction in direct ownership.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving RSU vesting and subsequent tax-related sales, are routine events in executive compensation structures across various industries. These transactions reflect the predetermined compensation plans rather than discretionary trading decisions.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a change in the company's operational or financial health. The executive retains a substantial stake, aligning interests.
• Employees: No direct impact on general employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations. It does not reflect discretionary selling or provide new information about the company's operational performance or future prospects. Therefore, it offers no basis for a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

West Pharmaceutical Services, WST, Chad Winters, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Stock Sale, Tax Withholding, Executive Compensation